DDInter1724 DDInter1376
Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Sulfamethoxazole {u} (Compound) resembles {v} (Compound) Sulfisoxazole
Sulfamethoxazole {u} (Compound) binds {v} (Gene) CYP2C8
Sulfamethoxazole {u} (Compound) upregulates {v} (Gene) SLC1A4
Sulfamethoxazole {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonamides
Sulfamethoxazole {u} (Compound) downregulates {v} (Gene) RPS4Y1
Sulfamethoxazole {u} (Compound) causes {v} (Side Effect) Purpura
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Toremifene
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Sulfamethoxazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methoxsalen
Sulfamethoxazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracaine
Sulfamethoxazole (Compound) resembles Sulfisoxazole (Compound)
Sulfamethoxazole (Compound) binds CYP2C8 (Gene)
Sulfamethoxazole (Compound) upregulates SLC1A4 (Gene)
Sulfamethoxazole (Compound) is included by Sulfonamides (Pharmacologic Class)
Sulfamethoxazole (Compound) downregulates RPS4Y1 (Gene)
Sulfamethoxazole (Compound) causes Purpura (Side Effect)
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Toremifene
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen
Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Tetracaine